Drug misuse a concern as new TB treatment faces delay in India

03/16/2013 | Business Standard (India)

Despite U.S. approval of bedaquiline drug Sirturo for treating multidrug-resistant tuberculosis, it faces potential delays in India, where the health minister says other research facilities are testing new TB treatments using bedaquiline. Experts are concerned that a culture of misuse that has rendered other drugs increasingly ineffective could do the same for bedaquiline in a country that, along with China, Russia and South Africa, represents 60% of MDR-TB cases in the world. "My biggest concern is you're introducing a brand new TB drug into one of the most unregulated chaotic drug markets you can see anywhere in the world," said Madhukar Pai, founder of the Pai Tuberculosis Research Group at Montreal's McGill University.

View Full Article in:

Business Standard (India)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC